UA75871C2 - 1,2,4-oxadiazole derivatives and use thereof as antagonists at metabotropic glutamate receptors - Google Patents

1,2,4-oxadiazole derivatives and use thereof as antagonists at metabotropic glutamate receptors Download PDF

Info

Publication number
UA75871C2
UA75871C2 UA2002032079A UA2002032079A UA75871C2 UA 75871 C2 UA75871 C2 UA 75871C2 UA 2002032079 A UA2002032079 A UA 2002032079A UA 2002032079 A UA2002032079 A UA 2002032079A UA 75871 C2 UA75871 C2 UA 75871C2
Authority
UA
Ukraine
Prior art keywords
oxadiazole
pyridyl
group
cyanophenyl
chloro
Prior art date
Application number
UA2002032079A
Other languages
English (en)
Ukrainian (uk)
Inventor
Methvin Benjamin Isaac
Original Assignee
Nps Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22530400&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA75871(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nps Pharma Inc filed Critical Nps Pharma Inc
Publication of UA75871C2 publication Critical patent/UA75871C2/uk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
UA2002032079A 1999-08-19 2000-08-18 1,2,4-oxadiazole derivatives and use thereof as antagonists at metabotropic glutamate receptors UA75871C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14946499P 1999-08-19 1999-08-19
PCT/US2000/022618 WO2001012627A1 (en) 1999-08-19 2000-08-18 Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists

Publications (1)

Publication Number Publication Date
UA75871C2 true UA75871C2 (en) 2006-06-15

Family

ID=22530400

Family Applications (1)

Application Number Title Priority Date Filing Date
UA2002032079A UA75871C2 (en) 1999-08-19 2000-08-18 1,2,4-oxadiazole derivatives and use thereof as antagonists at metabotropic glutamate receptors

Country Status (28)

Country Link
EP (1) EP1210344B1 (de)
JP (2) JP3790472B2 (de)
KR (1) KR100875222B1 (de)
CN (1) CN1313465C (de)
AT (1) ATE307129T1 (de)
AU (1) AU780191B2 (de)
BG (1) BG65586B1 (de)
BR (1) BR0013427A (de)
CA (1) CA2381975A1 (de)
CY (1) CY1105253T1 (de)
CZ (1) CZ2002599A3 (de)
DE (1) DE60023318T2 (de)
DK (1) DK1210344T3 (de)
EE (1) EE200200079A (de)
ES (1) ES2250177T3 (de)
HK (1) HK1047929A1 (de)
HU (1) HUP0202757A3 (de)
IL (2) IL148157A0 (de)
IS (1) IS6275A (de)
MX (1) MXPA02001764A (de)
NO (1) NO322460B1 (de)
NZ (1) NZ517221A (de)
PL (1) PL353825A1 (de)
RU (1) RU2296127C9 (de)
SK (1) SK2512002A3 (de)
UA (1) UA75871C2 (de)
WO (1) WO2001012627A1 (de)
ZA (1) ZA200201358B (de)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660753B2 (en) 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
EP1679313A3 (de) * 2001-02-21 2006-08-16 Nps Pharmaceuticals, Inc. Heteropolycyclische Verbindungen und ihre Verwendung als Antagonisten des metabotropischen Glutamat-Rezeptors
CA2442478C (en) 2001-04-02 2010-02-02 Mark F. Bear Use of group i mglur antagonists in the treatment of fragile x syndrome, autism, mental retardation
US6916821B2 (en) 2001-04-02 2005-07-12 Brown University Methods of treating disorders with Group I mGluR antagonists
JP4299139B2 (ja) * 2001-12-18 2009-07-22 メルク エンド カムパニー インコーポレーテッド 代謝型グルタミン酸受容体−5のヘテロアリール置換トリアゾールモジュレータ
US7569592B2 (en) * 2001-12-18 2009-08-04 Merck & Co., Inc. Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5
US20040259917A1 (en) * 2001-12-19 2004-12-23 Cosford Nicholas D.P. Heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5
DE60334781D1 (de) * 2002-03-12 2010-12-16 Merck Sharp & Dohme Di-aryl-substituierte tetrazol-modulatoren des metabotropen glutamat-rezeptors-5
SE0201943D0 (sv) * 2002-06-20 2002-06-20 Astrazeneca Ab New use
US7964609B2 (en) 2002-06-20 2011-06-21 Astrazeneca Ab Use of mGluR5 antagonists for the treatment of gerd
US20040132726A1 (en) * 2002-08-09 2004-07-08 Astrazeneca Ab And Nps Pharmaceuticals, Inc. New compounds
WO2004014902A2 (en) * 2002-08-09 2004-02-19 Astrazeneca Ab Compounds having an activity at metabotropic glutamate receptors
RU2352568C9 (ru) 2002-08-09 2009-06-27 Астразенека Аб [1,2,4]оксадиазолы (варианты), способ их получения, фармацевтическая композиция и способ ингибирования активации метаботропных глютаматных рецепторов-5
GB0303503D0 (en) * 2003-02-14 2003-03-19 Novartis Ag Organic compounds
CN100537564C (zh) * 2003-04-04 2009-09-09 麦克公司 代谢型谷氨酸受体-5的二芳基取代三唑调节剂
AU2004240586A1 (en) * 2003-05-15 2004-12-02 Merck & Co., Inc. 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as S1P receptor agonists
WO2005060961A2 (en) * 2003-12-18 2005-07-07 Astrazeneca Ab Treatment of transient lower esophageal sphincter relaxations (tlesrs) and gastro-esophageal reflux disease (gerd)
EP1711491A1 (de) * 2003-12-24 2006-10-18 Prosidion Limited Heterocyclische derivate als agonisten des gpcr-rezeptors
AU2005214380A1 (en) 2004-02-18 2005-09-01 Astrazeneca Ab Fused hetrocyclic compounds and their use as metabotropic receptor antagonists for the treatment of gastrointestinal disorders
US7585881B2 (en) * 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
PL1716152T3 (pl) * 2004-02-18 2009-01-30 Astrazeneca Ab Skondensowane związki heterocykliczne i ich zastosowanie jako antagonistów receptora metabotropowego do leczenia zaburzeń żołądkowo-jelitowych
CA2570318A1 (en) * 2004-06-30 2006-01-12 Banyu Pharmaceutical Co., Ltd. Biaryl derivatives
KR100621192B1 (ko) * 2004-10-13 2006-09-19 한국화학연구원 무스카린 수용체 작용물질로서 작용하는1,2,3,4-테트라하이드로피리미디닐-1,2,4-옥사다이아졸유도체와 이의 제조방법
JP4557685B2 (ja) 2004-11-15 2010-10-06 独立行政法人理化学研究所 蛍光蛋白質
RU2007125622A (ru) 2005-01-14 2009-02-20 Ф. Хоффманн-Ля Рош Аг (Ch) Производные тиазол-4-карбоксамида в качестве антагонистов mclur5
GB0510142D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
US20090054491A1 (en) * 2005-06-28 2009-02-26 Astrazeneca Ab Use
PL1907382T3 (pl) 2005-07-26 2016-01-29 Bial Portela & Ca Sa Pochodne nitrokatecholowe jako inhibitory COMT
AR058807A1 (es) 2005-09-29 2008-02-27 Astrazeneca Ab 5-(fenilisoxazoletoxi)-triazol-3-il piridinas sustituidas, para el tratamiento de trastornos mediados por el receptor mglur5
ES2382162T3 (es) 2005-11-08 2012-06-05 F. Hoffmann-La Roche Ag Derivados de tiazolo[4,5-c]piridina como antagonistas de receptor MGLU5
US7951824B2 (en) 2006-02-17 2011-05-31 Hoffman-La Roche Inc. 4-aryl-pyridine-2-carboxyamide derivatives
AU2007236707C1 (en) * 2006-04-03 2012-05-24 Astellas Pharma Inc. Hetero compound
EP1845097A1 (de) 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazolderivate als COMT Inihibitoren
US20100234349A1 (en) * 2006-09-04 2010-09-16 Olsen Gunnar M Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
AR062683A1 (es) 2006-09-07 2008-11-26 Actelion Pharmaceuticals Ltd Compuestos derivados de piridin-4-ilo, composicion farmaceutica que los contiene, y uso de los mismos en la preparacion de medicamentos
ES2400163T3 (es) 2006-09-08 2013-04-08 Actelion Pharmaceuticals Ltd. Derivados de piridil-3-ilo como agentes de inmunomodulación
WO2008035239A1 (en) 2006-09-21 2008-03-27 Actelion Pharmaceuticals Ltd Phenyl derivatives and their use as immunomodulators
ES2644049T3 (es) 2007-01-31 2017-11-27 Bial - Portela & Ca., S.A. Régimen de dosificación para inhibidores de COMT
SI2125797T1 (sl) 2007-03-16 2014-03-31 Actelion Pharmaceuticals Ltd. Derivati amino-piridina kot agonisti receptorja s1p1/edg1
SI2195311T1 (sl) * 2007-08-17 2011-07-29 Actelion Pharmaceuticals Ltd Derivati piridina kot modulatorji receptorja s1p1/edg1
AU2008319308B2 (en) 2007-10-31 2013-01-31 Merck Sharp & Dohme Corp. P2X3, receptor antagonists for treatment of pain
KR20100092473A (ko) 2007-11-01 2010-08-20 액테리온 파마슈티칼 리미티드 신규한 피리미딘 유도체
AU2008340733B9 (en) * 2007-12-20 2014-03-06 Ph Pharma Co., Ltd. 4-(4-Cyano-2-thioaryl)dihydropyrimidinones and use thereof
WO2009100438A2 (en) 2008-02-07 2009-08-13 Massachusetts Eye & Ear Infirmary Compounds that enhance atoh-1 expression
AU2009220893A1 (en) 2008-03-07 2009-09-11 Actelion Pharmaceuticals Ltd Novel aminomethyl benzene derivatives
BRPI0908731A2 (pt) 2008-03-17 2017-05-16 Bial - Portela & C A S A formas cristalinas de 5-[3-(2,5-dicloro-4,6-dimetil-1-óxi-piridina-3-il)[1,2,4]oxadiazol-5-il]-3-nitrobenzeno-1,2-diol
JP5592388B2 (ja) 2008-10-31 2014-09-17 メルク・シャープ・アンド・ドーム・コーポレーション 疼痛治療用のp2x3受容体アンタゴニスト技術分野
DE102008057364A1 (de) 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Substituierte Aryl-Verbindungen und ihre Verwendung
DE102008057343A1 (de) 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Heterocyclisch substituierte Aryl-Verbindungen und ihre Verwendung
DE102008057344A1 (de) 2008-11-14 2010-05-20 Bayer Schering Pharma Aktiengesellschaft Aminoalkyl-substituierte Aryl-Verbindungen und ihre Verwendung
DE102009041241A1 (de) 2009-09-11 2011-08-04 Bayer Schering Pharma Aktiengesellschaft, 13353 Substituierte Aryl-Verbindungen und ihre Verwendung
DE102009041242A1 (de) 2009-09-11 2011-12-15 Bayer Schering Pharma Aktiengesellschaft Heterocyclisch substituierte Aryl-Verbindungen und ihre Verwendung
US8946231B2 (en) 2009-03-23 2015-02-03 Merck Sharp & Dohme Corp. P2X3, receptor antagonists for treatment of pain
WO2010111058A1 (en) 2009-03-23 2010-09-30 Merck Sharp & Dohme Corp. P2x3, receptor antagonists for treatment of pain
EP2411001B1 (de) 2009-03-23 2018-01-17 Merck Sharp & Dohme Corp. P2x3-rezeptorantagonisten zur schmerzbehandlung
WO2010114404A1 (en) 2009-04-01 2010-10-07 Bial - Portela & Ca., S.A. Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof
US20120077854A1 (en) * 2009-04-13 2012-03-29 Irm Llc Compositions and methods for modulating retinol binding to retinol binding protein 4 (rbp4)
MX2012000414A (es) 2009-07-16 2012-02-08 Actelion Pharmaceuticals Ltd Derivados piridin-4-ilo.
WO2011109398A2 (en) 2010-03-02 2011-09-09 President And Fellows Of Harvard College Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
CN103313981B (zh) 2011-01-19 2016-05-11 埃科特莱茵药品有限公司 2-甲氧基-吡啶-4-基衍生物
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
PT2791134T (pt) 2011-12-13 2019-12-18 BIAL PORTELA & Cª S A Composto químico útil como intermediário para a preparação de um inibidor de catecol-o-metiltransferase
JP5946288B2 (ja) * 2012-02-24 2016-07-06 公立大学法人名古屋市立大学 新規ヒドロキサム酸誘導体及びその用途
CN108371182A (zh) * 2013-02-15 2018-08-07 孟山都技术公司 用于控制线虫害虫的3,5-二取代的-4,5-二氢-1,2,4-噁二唑
EP2853532B1 (de) * 2013-09-28 2020-12-09 Instytut Farmakologii Polskiej Akademii Nauk 1,2,4-Oxadiazoldrivate als allosterische Modulatoren von metabotropen Glutamatrezeptoren, die zur Gruppe-III gehören
WO2016083863A1 (en) 2014-11-28 2016-06-02 Bial - Portela & Ca, S.A. Medicaments for slowing parkinson's disease
US10385043B2 (en) 2015-05-20 2019-08-20 Idorsia Pharmaceuticals Ltd Crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol
AU2016281346B2 (en) 2015-06-23 2020-01-02 Kissei Pharmaceutical Co., Ltd. Pyrazole derivative, or pharmaceutically acceptable salt thereof
US11033545B2 (en) * 2016-03-30 2021-06-15 Sinntaxis AB Negative allosteric modulators of MGLUR5 for use in the treatment of mature brain damages
KR102276327B1 (ko) * 2019-06-25 2021-07-12 연세대학교 산학협력단 신규 옥사다이아졸 화합물 및 이를 포함하는 당뇨 예방 또는 치료용 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1149011B (de) * 1960-04-05 1963-05-22 Hoechst Ag Verfahren zur Herstellung von 3, 5-disubstituierten 1, 2, 4-Oxdiazolen
US3647809A (en) * 1968-04-26 1972-03-07 Chinoin Gyogyszer Es Vegyeszet Certain pyridyl-1 2 4-oxadiazole derivatives
US4003909A (en) * 1974-07-22 1977-01-18 E. R. Squibb & Sons, Inc. [(1,2,4-Oxadiazol-3-yl)phenyl]carbamic or thiocarbamic acid esters
US4022901A (en) * 1975-03-05 1977-05-10 E. R. Squibb & Sons, Inc. 3-Pyridinyl-5-isothiocyanophenyl oxadiazoles
AU675484B2 (en) * 1993-03-24 1997-02-06 Neurosearch A/S Benzimidazole compounds, their use and preparation
US5554630A (en) * 1993-03-24 1996-09-10 Neurosearch A/S Benzimidazole compounds
WO1994022846A1 (en) * 1993-03-30 1994-10-13 Pfizer Inc. Compounds enhancing antitumor activity of other cytotoxic agents
EP0821684B1 (de) * 1995-04-21 2001-12-05 NeuroSearch A/S Benzmidazolverbindungen und ihre verwendung als modulatoren des gabaa-rezeptor-komplexes
WO1997003967A1 (en) * 1995-07-22 1997-02-06 Rhone-Poulenc Rorer Limited Substituted aromatic compounds and their pharmaceutical use
DE19643037A1 (de) * 1996-10-18 1998-04-23 Boehringer Ingelheim Kg Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
AU771358B2 (en) * 1997-11-21 2004-03-18 Astrazeneca Ab Metabotropic glutamate receptor antagonists for treating central nervous system diseases

Also Published As

Publication number Publication date
NZ517221A (en) 2004-01-30
CZ2002599A3 (cs) 2002-06-12
WO2001012627A1 (en) 2001-02-22
BR0013427A (pt) 2002-07-30
RU2296127C2 (ru) 2007-03-27
BG106493A (en) 2003-01-31
NO20020823D0 (no) 2002-02-19
EP1210344B1 (de) 2005-10-19
EE200200079A (et) 2003-06-16
ATE307129T1 (de) 2005-11-15
HUP0202757A3 (en) 2006-03-28
NO322460B1 (no) 2006-10-09
AU780191B2 (en) 2005-03-03
CN1379775A (zh) 2002-11-13
HK1047929A1 (en) 2003-03-14
EP1210344A1 (de) 2002-06-05
IS6275A (is) 2002-02-18
JP3790472B2 (ja) 2006-06-28
RU2296127C9 (ru) 2007-08-27
JP2003507378A (ja) 2003-02-25
NO20020823L (no) 2002-04-17
CN1313465C (zh) 2007-05-02
KR20020038731A (ko) 2002-05-23
ES2250177T3 (es) 2006-04-16
AU6782400A (en) 2001-03-13
HUP0202757A2 (hu) 2002-12-28
ZA200201358B (en) 2003-07-30
PL353825A1 (en) 2003-12-01
DE60023318T2 (de) 2006-07-20
SK2512002A3 (en) 2002-07-02
BG65586B1 (bg) 2009-01-30
IL148157A0 (en) 2002-09-12
KR100875222B1 (ko) 2008-12-19
CY1105253T1 (el) 2010-03-03
DK1210344T3 (da) 2006-03-06
JP2006143746A (ja) 2006-06-08
DE60023318D1 (de) 2006-03-02
CA2381975A1 (en) 2001-02-22
MXPA02001764A (es) 2004-03-19
IL148157A (en) 2007-07-04

Similar Documents

Publication Publication Date Title
UA75871C2 (en) 1,2,4-oxadiazole derivatives and use thereof as antagonists at metabotropic glutamate receptors
JP6915003B2 (ja) ヒト血漿カリクレイン阻害剤
DE60221098T2 (de) Kondensierte heterocyclische derivate
TWI344955B (en) Heterocyclic rinf having nitrogen atom derivatives and medicament containing the derivatives as active ingredient
EA037257B1 (ru) Новые агонисты рецептора апелина и способы применения
KR101458007B1 (ko) 사이클로프로판 화합물
KR101666729B1 (ko) Mgat2 억제제로서의 아릴 디히드로피리디논 및 피페리디논
JP2008508307A (ja) カリウムチャンネル阻害剤
US10717727B2 (en) Pyridinium compounds
JP4790871B2 (ja) レニン阻害剤としての3,4−置換ピペリジン誘導体
KR20050109583A (ko) 나트륨 채널 차단제로서의 바이아릴 치환된 트리아졸
US20120165339A1 (en) Cyclopropane derivatives
US20030181472A1 (en) Inflammation modulators
CZ20023243A3 (cs) Pyrrolidinové deriváty, způsob jejich výroby, jejich pouľití a farmaceutický prostředek
JP2009514865A (ja) 有糸分裂キネシン阻害剤
WO2017008681A1 (zh) 酰胺类衍生物、其制备方法及其在医药上的用途
EP1582519A2 (de) Heteropolyzyklische Verbindungen und ihre Verwendung als Antagonisten von metabotropen Glutamatrezeptoren
TW201742857A (zh) 醯胺類衍生物、其製備方法、其藥物組合物及其在醫藥上的用途